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HHLA2 & IGPR1 ROLES IN TUMOR PROGRESSION AND METASTASIS 
ALVARO FERRIOL ALONSO 
ABSTRACT 
The metastatic pathways determine the process by which cancer cells give rise to a 
metastatic lesion in a new tissue or organ. Cell-cell adhesion is a central aspect of many 
of these metastatic pathways. Cell adhesion molecules belonging to the immunoglobulin 
superfamily (Ig-SF) commonly play a central role in cell-cell adhesion, and a number of 
these molecules have been associated with cancer progression and a metastatic 
phenotype. HERV-H LTR-associating protein 2 (HHLA2) and immunoglobulin-
containing and proline-rich receptor-1 (IGPR1) are two recently discovered IG-SF 
cellular adhesion molecules of the B7 and CD 28 family that are overexpressed in several 
cancer cell lines and contribute to increased growth, metastatic phenotype and decreased 
immune cell infiltration status. Regarding the accumulating evidence on the potential 
interaction between IGPR1 and HHLA2 in immune regulation we sought to explore the 
effects of this proposed interaction in the phosphorylation of IGPR1 on SER220. Our 
results show that HHLA2 reduces phosphorylation of IGPR1 at Ser220 in a in vitro co-
culture assay. Taken together, our data suggests that IGPR-1/HHLA2 pathway could 
regulate cell invasion and metastasis by stimulating and increased prosurvival and 
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Cell proliferation, migration, and differentiation are critically important during the 
development of all organisms, and it is the overall coordination of these activities that leads 
to the formation of complex structures such as tissues and organs [1]. These cellular 
processes are modulated by the interaction of cells with each other and with their 
microenvironment. Cell adhesion molecules (CAMs) facilitate these interactions and are 
essential during development and for maintenance of structural and functional integrity of 
the tissue architecture and requires highly dynamic cell-cell and cell-matrix interactions 
involving different types of surface receptors. Among these receptors, adhesion molecules, 
cadherins, and integrins play a major role by recognizing and interacting with other cell 
adhesion receptors on neighboring cells and by binding components of the ECM [54]. 
Besides providing mechanical anchorage to the cell, these structures also are of functional 
importance; they transduce signals from the ECM and neighboring cells that are critical for 
survival and proliferation. Loss of these signals frequently initiates apoptosis [55].[2,3]. 
CAMs include cadherins, integrins, selectins, and the immunoglobulin superfamily (IgSF). 
In normal tissue, CAM expression is tightly regulated. However, aberrant expression of 
CAMs disrupts normal cell-cell and cell-matrix interactions, freeing cells from normal 
check points and constraints, and facilitating tumor formation and metastasis [5]. One of 
the most important and ubiquitous types of adhesive interactions required for the 
maintenance of solid tissues is the cadherin adhesion molecules. Cadherins are 




important roles in cell recognition and cell sorting during development [56]. However, they 
continue to be expressed at high levels in virtually all solid tissues. There are many 
members of the classic cadherin family, but E-cadherin in epithelial tissues has been the 
most studied in the context of stable adhesions. Continued expression and functional 
activity of E-cadherin are required for cells to remain tightly associated in the epithelium, 
and in its absence the many other cell adhesion and cell junction proteins expressed in 
epithelial cells are not capable of supporting intercellular adhesion. In its capacity to 
maintain the overall state of adhesion between epithelial cells, E-cadherin is thought to act 
as an important suppressor of epithelial tumor cell invasiveness and metastasis [57]. Cell 
adhesion to ECM is essentially achieved through integrin-mediated linkage to extracellular 
ECM molecules and intracellular cytoskeleton. The large extracellular domain of integrins bind 
to ECM molecules while the intracellular domain is linked to cytoskeleton through intracellular 
focal adhesions (FAs) [59]. FAs are supramolecular complexes formed by more than 150 
different proteins, including kinases, scaffold and adaptor proteins, as well as actin linking 
proteins, they also mediate intracellular signaling pathways and are dynamic structures which 
assemble, disperse, and recycle during cell migration [58,60,61]. They also play critical roles 
in regulating other biological processes, such as apoptosis, proliferation, survival, and 
differentiation through integrin-mediated down-stream signaling pathways [61]. During cancer 
differentiation and metastasis processes, up-regulation of integrins has been linked to cancer 
invasiveness [62-64]. Selectins are vascular cell adhesion molecules involved in adhesive 
interactions of leukocytes and platelets and endothelium within the blood circulation. There 




functions of selectins are well described in processes of inflammation, immune response, 
wound repair, and hemostasis [65].  P-selectin is present in the storage granules of platelets 
(α-granules) and endothelial cells (Weibel-Palade bodies), thus enabling rapid 
translocation on cell surfaces upon activation. Endothelial expression of E-selectin 
requires de novo transcription, leading to expression on activated endothelial cell surfaces 
several hours after stimulation. L-selectin is constitutively expressed on cell surfaces of 
almost all leukocyte subpopulations [65,66]. The naturally occurring ligands for the three 
selectins are mostly mucin-type glycoproteins carrying sialylated, fucosylated glycans [67-
70]. In the normal physiological state, epithelial cells line the lumen of hollow organs and 
are covered by mucins that are either cell surface attached or building soluble layers 
covering the epithelium. Progression and poor prognosis of carcinomas are associated with 
enhanced expression of sialylated, fucosylated epithelial mucins. During malignant 
transformation cell surface glycans undergo dramatic changes that ultimately facilitates 
disseminating tumor cells in the blood ,not only interaction with endothelial cell selectins 
and tissue infiltration via rolling adhesion and diapedesis, but also permits malignant cells 
to bind platelets via selectins and coat themselves from their microenvironment 
potentiating even more the infiltration and seeding potential via platelet recruitment to 
endothelial lining ruptures forming microemboli that facilitate their arrest in the 
vasculature [71-73] 
To survive in tissue, epithelial cells must anchor to extracellular matrix (ECM), as 
detachment from it induces a specific programed cell death known as anoikis 




and proliferate without the requirement of anchorage to ECM (that is, anchorage-
independent growth) [7]. Emerging evidence suggests that as tumor cells lose the 
requirement for anchorage dependency for growth and survival, they increasingly rely on 
their ability to adhere to each other (that is, multicellular aggregation) for survival 
[9,10]. Invasive tumors frequently invade stroma in large groups by the mechanism of 
collective cell migration [11,12]. Circulating tumors of colorectal, breast, and prostate 
cancer are often present in aggregates and not in a single cell [13-17]. Tumor cell 
aggregation also significantly influences the cells’ response to cytotoxic drugs, as tumor 
cells in a spheroid environment are more resistant to radiation and chemotherapeutic 
agents, a phenomenon originally coined multicellular resistance (MCR) [18-20].  
Accumulating evidence on the role of cell–cell adhesion in tumor progression, and 
response to therapeutics suggests that tumor cell–cell interaction provides tumor cells an 
adaptive survival mechanism by which they overcome the need for anchorage dependency 
to ECM and evade the cytotoxic effects of chemotherapeutics. Additionally, this resistance 
to anoikis plays a major role in tumor metastasis conferring survival to these tumor cells 
after detachment from their primary location and they can then travel through the 
circulatory systems and subsequently use this increase in cell adhesion phenotype to anchor 
themselves in distant tissues [1,26,27]. Cancer metastasis is a process in which cancer cells 
disseminate from the primary tumor, settle and grow at a site other than the primary tumor site. 
The metastatic pathway describes the process by which cancer cells give rise to a metastatic 
lesion in a new tissue or organ. It consists of interconnecting steps all of which must be 




of these steps. Adhesion molecules belonging to the immunoglobulin superfamily (Ig-SF) 
commonly play a central role in cell-cell adhesion, and a number of these molecules have 
been associated with cancer progression and a metastatic phenotype. During metastatic 
spread, tumor cells disseminate to sites distant from the primary tumor, using cell migration 
mechanisms that are similar, if not identical, to normal physiological processes. The 
metastatic process consists of five sequential steps: (1) tumor cell proliferation and 
angiogenesis; (2) local cell invasion; (3) intravasation and dissemination; (4) extravasation; 
(5) metastatic colonization and proliferation [21-25]. Tumor cells also must escape 
immunological attack during any of these stages to survive by employing immune evasion 
tactics such as the overexpression of immune checkpoints that cause T-Cell exhaustion and 
dampening of the immunosurveillance and reduced elimination of carcinogenic cells. IgSF 
members have been implicated in most, if not all, of these processes [28,29].  
IgSF Superfamily: Tumorigenesis and Metastasis 
 The IgSF is one of the largest and most diverse families of proteins in the body. Members 
of the IgSF include major histocompatibility complex class I and II molecules, proteins of 
the T cell receptor complex, virus receptors [53] , and cell surface glycoproteins. The 
definitive characteristic of the IgSF members is the presence of one or more 
immunoglobulin like domains, which have a characteristic sandwich structure composed 
of two opposing antiparallel β-pleated sheets, stabilized by a disulphide bridge. Most of the 
IgSF members are type I transmembrane proteins, which typically consist of an 
extracellular domain (which contains one or more Ig-like domains), a single 




independent adhesion through their N-terminal Ig-like domains, which commonly bind 
other Ig-like domains of the same structure on an opposing cell surface (homophilic 
adhesion) but may also interact with integrins and carbohydrates (heterophilic adhesion). 
The C-terminal intracellular domains of IgSF members often interact with cytoskeletal or 
adaptor proteins. In this way, the extracellular interactions of IgSF CAMs can lead to 
signaling within the cell, enabling these proteins to function in a wide range of normal 
biological processes such as their vital role in embryonic development and by modulating 
cell–cell adhesion and cell migration, as well as pathological events such as inflammation 
and tumorigenesis. Several IgSF members have been identified as biomarkers for cancer 
progression. For example, MCAM (also called CD146, Mel-Cam, Muc18, and S-Endo1) 
has been implicated in the progression of melanoma, as well as in breast and prostate 
cancer. Similarly, IgSF members such as L1CAM (CD171), NCAM (CD56), PECAM-1 
(CD31), ALCAM (CD166), and ICAM-1 (CD54) have been associated with metastatic 
progression in a range of cancers including melanoma, glioma, breast, ovarian, 
endometrial, prostate, and colon cancer. IGPR1 and HHLA2 are new members of the IgSF 
CAM family with potential involvement in the progression and metastatic phenotype [1]. 
IGPR1: 
Immunoglobulin-containing and proline-rich receptor-1 (IGPR-1), a previously 
uncharacterized protein, was identified as a novel member in Ig-containing family of cell 
adhesion molecules. Ig containing adhesion molecules are involved in regulation of cell-
cell adhesion and cell migration in normal development and pathological conditions like 




specificity of cell-cell recognition while their Ig domain participate in protein-protein and 
protein-ligand interaction. IGPR-1 is expressed in various cell types including epithelial 
and endothelial cells. Interestingly, IGPR-1 gene has been found in advanced eukaryotes 
including primates, bovine, dolphins, canines, horses, etc. whereas, it is not present in rat 
or mouse genome.  IGPR-1 is mainly expressed by cells of epithelial origin, including 
bronchial epithelial cells of lung, breast glandular and lobular epithelia cells, urothelium of 
the bladder, skin epidermis, epithelium of gastrointestinal, and rectum. Moreover, 
endometrial glands of the uterus, the ureter, fallopian tube epithelium, colonic epithelium, 
small bowl epithelium, stomach epithelium, including both chief and parietal cells, 
trophoblastic epithelium of placenta, and pancreatic acinar cells were all positive for IGPR-
1. IGPR1 is found in a glycosylated form in the thymus, placenta, heart, small intestine, 
skin, and kidney with a molecular weight of 55 kDa while in the skeletal muscle, brain, 
colon, lung, and ovary IGPR1 is unglycosylated with an apparent molecular weight of 35 
kDa. Beyond epithelial cells that were positive for IGPR-1, endothelial cells present in vein 
and arteries also consistently were positive for IGPR-1. IGPR1 is expressed in various 
organs; however, its expression is mainly in epithelial and endothelial cell types. IGPR-1 
is comprised of three major domains: extracellular, transmembrane and intracellular. The 
extracellular domain of IGPR-1 contains a single immunoglobulin domain followed by a 







Figure 1. The deduced amino acid sequence of human IGPR-1. Amino acids 1–22 are a 
putative signal sequence (red). The immunoglobulin domain of IGPR-1 is shown (green), 




IGPR-1 seems to adapt a typical Ig V-like fold consisting of a sandwich of two antiparallel 
β-sheets. The immunoglobulin-containing extracellular domain is required for IGPR-1 to 
mediate endothelial cell–cell interaction and barrier function. IGPR-1 is localized at cell 
membrane in a di-sulfide linked cis-dimer structure. IGPR1 trans-homophilic dimerization 
with neighboring cells triggers phosphorylation of serine 220 at cytoplasmic region which 
is essential for IGPR-1 activation (Fig 2).  
Figure 2. Mechanism of IGPR-1 activation and function. (Wang et al., 2016) 
Deletion of the extracellular domain (ΔN-IGPR-1), which eliminated the trans-homophilic 
dimerization of IGPR-1 abrogated phosphorylation of Ser220 indicating that trans-
homophilic dimerization of IGPR-1 regulates Ser220 phosphorylation [30]. Importantly, 
IGPR-1 is highly glycosylated at its extracellular region and additional analysis showed 
that using glycosylation inhibitors caused IGPR-1 degradation.  In addition, it was 




regulates cell-cell adhesion and cell migration and it is required for angiogenesis. Further 
studies have shown that IGPR-1 plays a major role in vascular permeability and endothelial 
barrier function. To be more precise, IGPR-1 expression in porcine aortic cells (PAE) 
significantly increased trans-endothelial electrical resistance (TEER). Additionally, using 
fluorescently labeled dextran to verify vascular permeability, IGPR-1 expression decreased 
vascular permeability in PAE cells. The proline-rich intracellular domain of IGPR-1 is 
phosphorylated at multiple serine residues and associates with various Src homology 3 
(SH3) domain-containing proteins, including SPIN90/WISH (SH3 protein interacting with 
Nck), potentially linking IGPR-1 to actin polymerization via N-WASP and Arp2/3 
complex [29-30]. IGPR-1 expression is elevated in human primary colon cancers and 
promotes in vivo and in vitro tumor growth. Interfering with IGPR-1 activity by shRNA or 
blocking antibody inhibited growth of HCT116 cells. IGPR-1 distinctively promotes tumor 
growth by increasing multicellular aggregation of tumor cells. More importantly, IGPR-1 
expression in colon tumor cells significantly contributes to the development of resistance 
to the chemotherapeutic drug, doxorubicin [2]. In addition to its adhesive function, IGPR-
1 is proposed to bind to HHLA2, a member of the B7 family of costimulatory molecules 
involved in the activation and downregulation of T lymphocytes [31,32]. However, the 
biological relevance of HHLA2 interaction with IGPR1 remains unknown. 
HHLA2 
HHLA2 (B7H7) has recently been identified as a new member of the B7 family member 
[33,34]. HHLA2 was initially discovered as a gene in the Immunoglobulin (Ig) superfamily 




terminal repeat (LTR) sequences which provide polyadenylation signals [35]. Hence the 
name, HHLA2, is short for HERV-H LTR-associating 2. HHLA2 orthologs appear to be 
present in a wide range of species such as fish, frog, giant panda, monkey and human, but 
not in laboratory mouse and rat strains. The HHLA2 protein has amino acid similarity of 
23 to 33% to the other human B7 family molecules and phylogenetically it is most similar 
to B7-H3 and B7x (B7-H4/B7S1). The predicted structure of HHLA2 is a type I 
transmembrane molecule with three extracellular Ig domains (Fig 3). 
 
Figure 3. A structural representation of the B7 and CD28 family members.  
This is unique as most other B7 family members contain only two Ig domains while human 
B7-H3 has four Ig domains. Most normal organs do not express HHLA2 at the protein 
level; however, trophoblastic cells of the placenta and epithelial cells of the gut, kidney, 
gallbladder and breast expressed this ligand. Additionally, HHLA2 is constitutively 
expressed on human monocytes and induced on B cells after stimulation with IFN-γ, while 




appeared to stain positively in these samples. These results reveal that endogenous HHLA2 
protein is absent in most normal tissues, but mainly expressed on epithelial cells of a few 
tissues. HHLA2 does not interact with other known members of the CD28 family or the 
B7 family but does bind a putative receptor that is constitutively expressed not only on 
resting and activated T cells but also on APCs. In 2013, Zhu and colleagues found that 
TMIGD2/IGPR1/CD28 homologue (CD28H) bound to HHLA2 on APCs. In 2015, 
Janakiram et al found that HHLA2-Ig bound to cells expressing Transmembrane and 
Immunoglobulin Domain Containing 2 (TMIGD2) and TMIGD2-Ig bound strongly to 3T3 
cells expressing HHLA2. Since HHLA2 belongs to the B7 family, it is hypothesized that 
HHLA2 regulates T cell function. HHLA2 immunoglobulin fusion protein (HHLA2-Ig) 
binds to T cells (resting and activated) and other immune cells demonstrating that there are 
constitutive receptors on the cell surface. HHLA2-Ig can decrease both CD4 and CD8 T 
cell proliferation when incubated with anti-CD3. Functionally incubating T cells with 
HHLA2-Ig decreases the production of several cytokines including IFN-γ, TNF-α, IL-5, 
IL-10, IL-13, IL-17A, and IL-22. HHLA2 also inhibits IL-2 secretion by T cells in a dose 
dependent manner. These experiments demonstrate that HHLA2 inhibits T cell 
proliferation and function. HHLA2 also functions as a costimulatory molecule and 
increases cytokine production. It is not uncommon for members of the B7 family to have 
dual functions depending on the immune milieu, receptor engagement or blockade or 
interaction with different receptors. Overall these studies demonstrate that HHLA2 





IGPR1 & HHLA2 Tumorigenesis and Metastatic Potentiation 
Apoptotic Evasion. The first step in metastasis is the transformation of cells from a normal 
to a cancerous phenotype. This is when cells acquire characteristics that help them to 
withstand factors that may limit their metastatic spread. These factors include genotypic 
stress, tissue hypoxia, nutrient depletion, the accumulation of toxic metabolites, 
haemodynamic shearing, and loss of adhesion. Most cells encountering these factors will 
undergo apoptosis (preprogrammed cell death). However, genome expression analysis of 
metastatic tumors using cDNA microarrays has revealed a strong correlation between 
tumor progression and the loss of expression of proapoptotic genes, with a concomitant 
gain in expression of antiapoptotic genes [24,25]. Thus, the acquisition of apoptotic 
resistance in cells under stress is the first requirement in tumor progression toward 
metastasis. Classically, genotypic stress due to genomic instability through DNA mutation, 
chromosomal rearrangement, and epigenetic alteration will trigger apoptosis through the 
tumor suppressor p53 (TS P53) pathway. In many tumor cells, the expression of TS P53 is 
lost, enabling them to avoid apoptotic death [36]. However, this accounts for only 40% of 
cells that undergo malignant transformation. Recent reports have indicated that aberrant 
expression of CAMs such as the IgSF members provides antiapoptotic signals that may 
account for the other 60% of malignant transformation. For example, Campodónico et al. 
reported that the functional blockade of NCAM led to susceptibility to apoptosis in murine 
lung tumor cells and suggested that NCAM expression may be linked to apoptotic 
resistance in these cells. This resistance seems to be due to activation of the transcription 




such as B-cell lymphoma/leukemia-x long (Bcl-x1), X-linked inhibitor of apoptosis protein 
(XIAP), and cellular inhibitor of apoptosis protein (C-IAP) [37-39]. MCAM expression by 
melanoma cells has also been shown to activate NF-κB via the upstream p38 mitogen-
activated protein kinase (MAPK) [40]. Inhibition of MCAM using a blocking monoclonal 
antibody led to downregulation of p38 MAPK phosphorylation, the suppression of NF-κB 
activation, and a decrease in tumor growth, possibly due to cell death through apoptosis 
[41]. Similarly, IGPR-1 increased survival of both HT29 and HCT116 cells in suspension 
condition and analysis of phosphorylation of p38 in HT29 cells showed that in HT29 cells 
expressing IGPR-1, phosphorylation of p38 was significantly inhibited, suggesting that the 
prosurvival effect of IGPR-1 in Colorectal Cancer tumor cells in the absence of adhesion 
to ECM is mediated by reducing activity of the stress-induced p38.  Interfering with IGPR-
1 activity by shRNA or blocking antibody inhibited growth of HCT116 cells [2]. 
Angiogenesis. Acquisition of angiogenesis by tumor cells is considered the most critical 
step in tumor growth and metastasis. To grow beyond 2 mm in diameter, a tumor needs to 
undergo angiogenesis, which is often established by hypoxia-induced expression of VEGF 
and other hypoxia-induced growth factors. It has been shown that IGPR1 stimulates 
angiogenesis and that modulation of expression of IGPR-1 by ectopic expression or 
silencing in endothelial cells significantly altered the angiogenic phenotype of endothelial 
cells in culture and introducing IGPR-1 to tumor cells increased tumor angiogenesis via 
SPIN90 association through its SH3 domain [29]. Taken together, IGPR-1 promotes 
multicellular aggregation in tumor cells, increases tumor growth in vivo and in vitro, and 




Dissemination and Immune Evasion Once tumor growth has reached a critical mass, the 
metastatic spread of tumor cells is dependent on their dissociation from the primary tumor 
and migration towards the systemic circulation. Primary tumors with invasive properties 
usually display reduced intercellular adhesion, which allows cells to break away from the 
parental cell mass. Intravasation of tumor cells is not well understood, but it is generally 
believed that tumor cells can pass easily into the irregular, highly permeable blood vessels 
formed during tumor angiogenesis [42]. Once inside the vasculature, less than 0.1% of 
these circulating tumor cells (CTCs) are estimated to remain viable after 24 hours and less 
than 0.01% survive to generate metastases [43]. This may be due to anoikis, the result of 
fluid shear forces, or immunological attack. Anoikis is an apoptotic process triggered by 
the loss of cell-matrix interactions and the ability to overcome this is crucial for CTC 
survival [44]. As beforementioned IGPR1 confers anoikis resistance and increased survival 
in suspension conditions. Moreover, tumor multicellular aggregation promotes cell 
survival and expression of IGPR-1 by tumor cells contributes to multicellular aggregation 
and tumor cell survival. Tumor cells often coopt to cellular aggregation by interacting with 
each other or other cell types to lessen the cytotoxic effects of chemotherapeutics, a 
phenomenon known as ‘multicellular resistance’. Multicellular resistance occurs in 
response to a variety of anti-cancer strategies, including chemotherapy and ionizing 
radiation and IGPR-1 by modulating phosphorylation of histone H2AX acts to reduce the 
sensitivity of tumor cells toward the DNA-damaging agent, doxorubicin. IGPR-1 provides 
a unique ability to evade apoptosis, grow without anchoring to ECM, and develop 




prosurvival effects, IGPR-1 binds to HHLA2, a member of the B7 family of coinhibitory 
molecules involved in the downregulation of T lymphocytes activation [2]. Given that 
HHLA2 inhibits IGPR1 function it is possible that, through downregulation or inhibition 
of IGPR1 phosphorylation at Ser220, HHLA2 increases endothelial cell permeability and 
facilitates tumor cell infiltration to the vasculature by loosening tumor cell cohesion and 
disrupting endothelial cell junctions [1,22-24,29-33,43]. In accordance with this 
hypothesis, it has been found that HHLA2 expression in Osteosarcoma, PD-L1 
negative non-small cell lung carcinoma, bladder urothelial carcinoma, colorectal 
carcinoma and triple negative breast cancer increases metastatic phenotype, lymph node 
metastasis and tumor aggressiveness and is correlated with a decreased T-cell infiltration 
status [31,32, 45-51]. In agreement with a possible role of IGPR-1 in cell adhesion and 
cell–cell interaction, expression of IGPR-1 in PAE cells and B16F cells inhibits cell 
migration [29]. Of interest, the reduced migration of these cells by IGPR-1 also correlates 
with the inhibition of phosphorylation of paxillin at tyrosine 118 (Y118). Phosphorylation 
of Y118 of paxillin is linked to inhibition of cell migration suggesting that IGPR-1 inhibits 
cellular migration, in part by stimulating dephosphorylation of paxillin either by increasing 
protein phosphatase activity or preventing its phosphorylation by inhibiting tyrosine 
kinases such as Src family kinases and focal adhesion kinases, which are involved in the 
phosphorylation of paxillin [29]. The wide expression of HHLA2 in human cancers and its 
association with more invasive disease suggests that HHLA2 potentially plays an important 




mediated tumor cell adhesiveness, increased cellular migration phenotype and the 
disruption of endothelial cell permeability. 
 
Specific aims:  
The overall goal of this project was to investigate the potential effect of HHLA2 in IGPR-
1 activation.  Specifically, the specific aims of this project were:  
Specific aim I: Examine expression of profile of IGPR-1 and HHLA2 in a panel of human 
tumor cell lines. 












Antibodies and Reagents 
 
Rabbit polyclonal antibody against HHLA2 protein was purchased from Fisher 
Scientific (Rockford, IL). It was used diluted 1:1000 in Blotto and used in 
Western blots to detect the presence of HHLA2 in HEK-293 cells. Rabbit 
polyclonal anti-IGPR-1 antibody was made against a peptide derived from the 
cytoplasmic domain of IGPR-1 as previously described [29]. Anti-IGPR1 
antibody was used diluted 1:5000 in Blotto solution and used for Western blot 
analysis to detect expression of IGPR1 in HEK-293 cells and colon cancer cell 
lines. Anti-phospho-serine 220 IGPR-1 (pSer220) antibody was developed 
using a peptide containing phospho-serine 220 and further purified by peptide 
affinity chromatography using phospho-serine220 containing peptide as 
previously described [30]. Anti-pSer220 antibody was used in 1:1000 dilutions 
for Western blot analysis.  
Cell Culture 
 
Human Embryonic Kidney cells (HEK-293)(ATCC) were grown and 
maintained in Dulbecco’s Modified Eagle’s Media (DMEM) containing 10% 
fetal bovine serum (FBS) and 50 units/mL penicillin and streptomycin. Cells 
were placed in a humidified incubator at 37°C and 5% CO2. Cells were sub-
cultured by using 2 mL of 0.05% trypsin/EDTA for 2 minutes in 47 mm plates while 




lysates were provided by the Dr. Rahimi Lab from previous experiments and were 
stored in -20 Cº freezer. 
 
Plasmids and constructs 
 
The cDNA of HHLA2-HisTag was purchased from Invitrogen (Carlsbad, CA), 
was PCR amplified and cloned into retroviral vector pMSCV with puromycin 
resistance gene (Invitrogen, Carlsbad, CA) via XhoI and EcoRI. Similarly, 
cDNA corresponding to IGPR1 was purchased from Invitrogen (Carlsbad, CA), 
and was PCR amplified and cloned into retroviral vector pMSCV via HindIII 
and SalI restriction sites. To confirm for insertion the vectors where analyzed 
by agarose gel electrophoresis. Expression was confirmed in subsequent 





HEK-293 cells were grown in DMEM 10% FBS and 50 units/mL penicillin and 
streptomycin medium to 60% confluency .Prior to transfection, the medium was 
removed and 2 mL of serum free DMEM was added to each 47 mm cell culture 
dish. DNA-PEI (polyethylenimine) mixtures were prepared containing 400µl of 
serum-free DMEM, 9µg of PEI and 3µg DNA from pMSCV-HHLA2-HisTag 
or pMSCV-IGPR1 and incubated for 15 minutes at room temperature. The 




to each plate respectively (3 plates) and the cells were returned to 37°C 
incubator. After 6 hours, 2mL of DMEM 10% FBS was added to each plate and 
the next day (16-20 hours), all of the medium was replaced with 4 ml DMEM 
10% FBS (2 µg/ml puromycin) for selection of transfected colonies.  
 
Retrovirus Production and Transduction 
 
In order to perform retroviral virus production, 293-derived retroviral 
packaging cell line (293GPG) cells were maintained at 90% confluence in 293 
GPG Growth Media containing Dulbecco's modified eagle medium (DMEM), 
10% (vol/vol) fetal bovine serum (FBS) , 2 mM L-glutamine ,50 units/ml each 
of penicillin and streptomycin , 1 ,ug/ml tetracycline, 2 µg/ml puromycin and 
0.3 mg/ml G418 [52]. Then the 293 GPG cells were transfected with pMSCV-
HHLA2-HisTag or pMSCV-IGPR1. After 24 hours, the media was replaced 
with viral producing medium (293 GPG media without tetracycline) and at 72, 
96, 120, and 144 hours the virus was collected as described [52]. .  , 4ml of virus 
and 2µl of polybrene were added to HEK-293 cells at 70% confluence in a 
60mm plate. DMEM 10% FBS with appropriate selection antibiotic (2 µg/ml 
puromycin and 0.3 mg/ml G418) was added to select for transduced cells. Cells 
were monitored for 3 days in the incubator at 37 ºC to ensure survival in 
antibiotic media before confirming successful transduction. After successful 




Western Blot Analysis 
 
HEK-293 , HEK-293 HHLA2-His Tag and HEK-293 IGPR1 cells  
60mmculture dishes were placed on ice, rinsed twice with chilled H/S buffer 
[20 mM Hepes (pH 7.4) and 150 mM NaCl] then lysed using lysis buffer  
containing 10uL/ml Na3VO4 and 15 ul/ml PIC (Protease Inhibitor Cocktail) 
[500 μM AEBSF 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, 
150 nM aprotinin, bovine lung, crystalline, 1 μM E-64 protease inhibitor, 0.5 
mM EDTA, disodium, and 1 μM leupeptin, hemisulfate] for every mL of EB 
buffer [10mM Tris- HCl (pH 7.5), 10 mM EDTA, 50 mM NaCl, 50 mM NaF, 
1%Triton X-100]. Whole cell lysates were centrifuged. Then, 5X sample 
buffer [3.8% Tris-base, 50% glycerol, 5% sodium dodecyl sulphate (SDS), 5% 
β-mercaptoethanol, and .0025% bromophenol blue] was added to each 
collected supernatant and samples were boiled at 95°C for 5 minutes. Cell 
lysates were loaded on a 12% SDS polyacrylamide gel and subjected to 
electrophoresis (SDS-PAGE), then transferred onto polyvinylidene difluoride 
(PVDF) membranes pre-activated by methanol. PVDF membranes were 
blocked with Blotto (2% non-fat dry milk and 0.05% Tween-20 in Western 
Rinse) and for HHLA2 blots we used Bovine Serum Albumin blocking buffer 
for 1 hour on a rocker at room temperature. Following washing with Western 
rinse [25 mM Tris -HCl (pH 7.2), 0.05% Tween-20 and 0.15 mM NaCl for 5 
minutes at r, membranes were immunoblotted with the respective primary 
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antibodies for 1 hour at room temperature. After three washes with Western 
rinse (each time 10 minutes), membranes were incubated with the respective 
secondary antibodies for 1 hour at room temperature. Following three 10 
minutes washes with Western rinse membranes were  (0.1M Tris pH 8.5, 
0.2mM coumaric acid and 1.25mM Luminol mixed with 0.12% (w/w) 






Expression of HHLA2 and IGPR-1 in human cancer cell lines 
 
Expression of IGPR1 and HHLA2 is shown for several Renal and Colon cancer cell lines 
(Fig. 4). There seems to be a discrepancy between the relative expressions of both which 
raises the question for future research as to how HHLA2 expression levels affect IGPR1 
expression in a co-expression cell line system and eventually in an wild type cancer cell 
line. 
 













HHLA2 inhibits phosphorylation of IGPR1 at pSer220 
 
Considering the important role of phosphorylation of IGPR1 at Ser220 we sought to 
explore the potential function of HHLA2 in the phosphorylation of IGPR1 at Ser220. The 
result showed that co-culture of HEK293 HHLA2 and IGPR1 for 48 hours significantly 
reduced phosphorylation of IGPR1 at Ser220 (Fig.2) 
 
 
Fig. 5 IGPR1 phosphorylation at Ser220 is inhibited after co-culture with HHLA2 
















The metastatic pathway describes the process by which cancer cells give rise to a metastatic 
lesion in a new tissue or organ. It consists of interconnecting steps all of which must be 
successfully completed to result in a metastasis. Cell-cell adhesion is a key aspect of many 
of these steps. Adhesion molecules belonging to the immunoglobulin superfamily (Ig-SF) 
commonly play a central role in cell-cell adhesion, and a number of these molecules have 
been associated with cancer progression and a metastatic phenotype. The metastatic 
process consists of five sequential steps: (1) tumor cell proliferation and angiogenesis; (2) 
local cell invasion; (3) intravasation and dissemination; (4) extravasation; (5) metastatic 
colonization and proliferation [21-25]. Tumor cells also must escape immunological attack 
during any of these stages to survive by employing immune evasion tactics such as the 
overexpression of immune checkpoints that cause T-Cell exhaustion and dampening of the 
immunosurveillance and reduced elimination of carcinogenic cells.  
IGPR-1 is a novel adhesion molecule, which is widely expressed in endothelial and 
epithelial cells [29-30]. IGPR1 trans-homophilic dimerization with neighboring cells 
triggers phosphorylation of serine 220 at cytoplasmic region which is essential for IGPR-
1 activation and function in cell-cell adhesion, endothelial barrier function, and regulation 
of angiogenesis which contribute to increased growth in the primary tumor and stimulation 
of angiogenesis [29-30]. Expression of IGPR-1 in PAE cells and B16F cells inhibits cell 
migration and inhibition of IGPR1 increases vascular permeability [29]. IGPR-1 
expression is elevated in human primary colon cancers and promotes in vivo and in 




inhibited growth of HCT116 cells, suggesting that targeting IGPR-1 could offer a novel 
anti-cancer strategy. IGPR-1 distinctively promotes tumor growth by increasing 
multicellular aggregation of tumor cells. In addition to its adhesive function and 
prosurvival effects, IGPR-1 binds to HHLA2, a member of the B7 family of coinhibitory 
molecules involved in the downregulation of T lymphocytes activation [2].  
HHLA2 is a newly discovered T cell immune checkpoint molecule that belongs to the B7 
family of ligands. It predominantly functions to inhibit T cell proliferation and T cell 
cytokine responses. HHLA2 is expressed on few normal tissues but it is expressed in 
various human cancers. High expression of HHLA2 in human cancer of lung, breast, and 
osteosarcoma is associated with worse prognostic features and increased lymph node 
positivity. It has been found that HHLA2 expression in Osteosarcoma, PD-L1 
negative non-small cell lung carcinoma, bladder urothelial carcinoma, colorectal 
carcinoma and triple negative breast cancer increases metastatic phenotype, lymph node 
metastasis and tumor aggressiveness and is correlated with a decreased T-cell infiltration 
status [31,32, 45-51].  
Considering that HHLA2, inhibits phosphorylation of pSer220 on IGPR1 it is possible that 
this interaction may contribute to local cell invasion in the primary tumor site by disrupting 
cell cohesion in the epithelia. Additionally, this inhibition may potentiate intravasation into 
the vasculature by interfering with endothelial cell-cell adhesiveness and increasing 
vascular permeability through IGPR inhibition. Moreover, HHLA2 may potentiate 
dissemination throughout the vasculature and through the epithelial layer by increasing 




of CD4 and CD8 through HHLA2 T-Cell inhibition may potentiate even further the 
metastatic phenotype by shielding the traveling multicellular aggregates from immune 
surveillance and attack [33].  
Given the contradictory roles of IGPR1 in promoting survival and growth and HHLA2 
negatively regulating IGPR1 phosphorylation at pSer220 it is imperative to explore the 
roles of these seemingly antagonistic proteins in the potentiation of growth and metastatic 
phenotype. Additionally, it is important to explore the timing and microenvironmental 
conditions that stimulate the expression of these two proteins as well as localization of 
these proteins relative to the primary tumor mass. Probably IGPR1 expression comes first 
to allow primary tumor cells to override growth signaling pathways through inhibition of 
p38MAPK and protect themselves from possible chemotherapeutic agents by increasing 
the number of focal adhesions through IGPR1 trans-dimerization between epithelial tumor 
cells. In addition, IGPR also helps to establish blood flow to the tumor by stimulating 
angiogenesis [2,29]. Then HHLA2 expression by peripheral tumor cells of the primary 
tumor may help them increase vascular permeability, detach from other IGPR1 expressing 
outside of the mass and evade immune elimination by downregulating T-Cell Activation. 
The wide expression of HHLA2 in human cancers and its association with more invasive 
disease suggests that HHLA2 potentially plays an important role in tumor evolution and 
metastases through immune suppression, inhibition of IGPR1 mediated tumor cell 
adhesiveness, increased cellular migration phenotype and the disruption of endothelial cell 
permeability. Hopefully, further studies on this inhibitory HHLA2 pathway may lead to 
new therapies for human cancers and possibly autoimmune diseases. 
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